Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-activated inward rectifier potassium channel 2 (GIRK2), encoded by the KCNJ6 gene, is a critical membrane protein that modulates cellular excitability in the central nervous system [1, 2]. It acts as a primary effector for various G protein-coupled receptors (GPCRs), including opioid, GABA-B, and dopamine receptors, by opening in response to the binding of G-beta-gamma subunits [6, 12]. This activation facilitates the efflux of potassium ions, resulting in membrane hyperpolarization and the inhibition of neuronal firing [10, 16]. GIRK2 is widely expressed in the brain, where it exists as homotetramers or heterotetramers with other subunits like GIRK1 and GIRK3 [12, 17].\n\nDysfunction of GIRK2 is linked to several neurological and developmental disorders. Mutations in KCNJ6 cause Keppen-Lubinsky syndrome, characterized by severe developmental delay and intellectual disability [2, 13]. Additionally, GIRK2 overexpression is a significant factor in the cognitive impairments associated with Down syndrome [8, 9]. The channel is also involved in the pathophysiology of neuropathic pain, epilepsy, and substance use disorders, particularly alcohol and nicotine addiction [9, 12]. While GIRK2 represents a promising therapeutic target for analgesia and neurological conditions, drug development faces challenges in achieving subunit selectivity to avoid off-target effects, such as cardiac arrhythmias mediated by related GIRK channels in the heart [6, 12].
Activation of the channel by G-protein beta-gamma subunits (released from Gi/o-coupled GPCRs) leads to potassium efflux, causing membrane hyperpolarization and inhibition of cellular excitability [6, 12, 16].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-activated inward rectifier potassium channel 2 (GIRK2) (GIRK2).